Overview

Study to Evaluate the Safety, Tolerability and Pharmacokinetics of PF-04958242 in Healthy Adult Volunteers

Status:
Terminated
Trial end date:
2011-05-03
Target enrollment:
Participant gender:
Summary
The primary objective of this study evaluates the safety and tolerability of multiple, escalating doses of PF-04958242 administered orally to healthy adult participants.This study also evaluates the plasma and urine multiple dose pharmacokinetics (PK) of PF-04958242.
Phase:
Phase 1
Details
Lead Sponsor:
Biogen
Pfizer